Company profile

Hybrigenics is a biopharmaceutical company. Hybrigenics and its subsidiaries constitute the DMS Biotech division, which carries the development strategy of DMS (Diagnostic Medical Systems) in the field of biotechnologies, particularly technologies for the treatment of osteoarthritis and regenerative medicine based on the injection of adipose stem cells. Hybrigenics and Servier collaborated on a specific ubiquitin protease that is particular to oncology. In this R&D program, two milestones have been achieved and additional milestones are likely to be reached up to the potential registration of a drug.

Source: Cofisem - Last Update: 28 Jul 2020
Key Executives
Chief Executive Officer Julien Gauthier
Source: Cofisem - Last Update: 09 Jul 2020
Key figures
Millenium 2019 2018 2017 2016 2015
Net sales 235 77 2,518 4,641
Consumed purchases 1 31 113 2,604
Payroll 770 2,509 3,023 2,429 5,351
Operating profit -1,361 -7,638 -7,377 -4,320 -4,414
Income tax 60 348 0
Net income -736 -7,528 -7,957 -5,252 -4,340
Net consolidated income (Group share) -736 -7,528 -7,957 -5,257 -4,376
Fiscal year end 12.19 12.18 12.17 12.16 12.15
Length of fiscal year (month) 12 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards
Source: Cofisem - Last Update: 28 Jul 2020
Shareholder information
DMS (Diagnostic Medical Systems) 79.67 %
Source: Cofisem - Last Update: 09 Jul 2020

Financial analysis

Equity research report, in partnership with Morningstar

View Report

Address

Hybrigenics

393 Rue Charles Lindbergh
FR-34130 Mauguio
France
Source: Cofisem - Last Update: 28 Jul 2020

Contact

Julien Gauthier
Phone number: +33158103800
Source: Hybrigenics - Last Update: 28 Jul 2020